Multiple Myeloma Epidemiology Forecast

DelveInsight’s ‘Multiple Myeloma Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted MM epidemiology in the 8MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China

Study Period: 2017–2030

Multiple Myeloma (MM) Understanding

According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74.


Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow.


Multiple Myeloma Diagnosis

Multiple myeloma is often diagnosed based on tests, the patient’s symptoms and the doctor’s physical exam of the patient. A diagnosis of multiple myeloma requires either:


1. A plasma cell tumor (proven by biopsy) or at least 10% plasma cells in the bone marrow

2. At least one of the following:

  • High blood calcium level
  • Poor kidney function
  • Low red blood cell counts (anemia)
  • Holes in the bones from tumor found on imaging studies (CT, MRI, PET scan)
  • Increase in one type of light chain in the blood so that one type is 100 times more common than the other
  • 60% or more plasma cells in the bone marrow

Epidemiology Perspective by DelveInsight

The Multiple Myeloma epidemiology division provides insights about historical and current patient pool and forecasted trends for each eight major countries. The Multiple Myeloma epidemiology data are studied through Multiple Myeloma possible division to give a better understanding of the Disease scenario in the 8MM.


The disease epidemiology covered in the report provides historical as well as forecasted Multiple Myeloma epidemiology [segmented as Total Incidence of Multiple Myeloma, Total Symptomatic Cases of Multiple Myeloma, Total Incident Cases of Multiple Myeloma Segmented by Gender, Total Diagnosed cases of Multiple Myeloma by Age Distribution, Total Cases of Multiple Myeloma by Line of Treatment] scenario of Multiple Myeloma in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030.

Multiple Myeloma Detailed Epidemiology Segmentation

  • In the year 2020, the total incident case of Multiple Myeloma was 91,693 cases in the 8MM. The United States, in 2020, accounted for 32,270 cases (the highest number), which will probably rise by the year 2030. Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma in the year 2020, was in Germany. In China, the total number of incident cases of Multiple Myeloma was 21,116 in 2020, and this number is expected to rise throughout the forecast period.
  • The overall number of symptomatic cases of Multiple Myeloma in the 8MM was 80,715, and these cases are expected to rise by 2030.
  • Males are more likely to develop Multiple Myeloma than females (about 55 percent of cases). When it comes to age-specific Multiple Myeloma cases, the age group 65–74 years has by far the most, followed by 75–84 years and 55–64 years.
  • In the 8MM, the total cases of Multiple Myeloma by treatment line were 23,581 cases for frontline transplant-eligible patients, 49,699 cases for frontline transplant-ineligible patients, 44,955 cases for second-line patients, 23,498 cases for third-line patients, and 10,236 cases for fourth-line plus patients, in the year 2020.

Scope of the Report

  • The Multiple Myeloma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The Multiple Myeloma Report and Model provide an overview of the risk factors and global trends of MM in the eight major markets (8MM: United States, Germany, France, Italy, Spain, and the United Kingdom, Japan, and China).
  • The report provides insight about the historical and forecasted patient pool of Multiple Myeloma in eight major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan and China, and China.
  • The report helps to recognize the growth opportunities in the 8MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Multiple Myeloma.
  • The report provides the segmentation of the Multiple Myeloma epidemiology by total Incidence of cases in the 8MM.
  • The report provides the segmentation of the Multiple Myeloma epidemiology by total symptomatic cases in the 8MM.
  • The report provides the segmentation of the Multiple Myeloma epidemiology by Age and Gender in the 8MM.
  • The report provides the segmentation of the Multiple Myeloma epidemiology by Line-wise treated Patient Pool in the 8MM.

Report Highlights

  • 10-Year Forecast of Multiple Myeloma epidemiology
  • 8MM Coverage
  • Total Incident Cases of Multiple Myeloma in the 8MM
  • Total Symptomatic Incident Cases of Multiple Myeloma in the 8MM
  • Incident Cases of Multiple Myeloma according to segmentation: Age, and Gender
  • Treated cases of Multiple Myeloma

KOL-Views

We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over Multiple Myeloma scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 8MM with respect to the patient population pertaining to Multiple Myeloma?
  • What are the key findings pertaining to the Multiple Myeloma epidemiology across the 8MM and which country will have the highest number of patients during the study period (2017–2030)?
  • What would be the total number of patients of Multiple Myeloma across the 8MM during the study period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
  • At what CAGR the patient population is expected to grow in the 8MM during the study period (2017–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Multiple Myeloma?

Reasons to buy

The Multiple Myeloma Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Multiple Myeloma market
  • Quantify patient populations in the global Multiple Myeloma market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Multiple Myeloma therapeutics in each of the markets covered
  • Understand the magnitude of Multiple Myeloma population by its severity
  • The Multiple Myeloma epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Multiple Myeloma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Multiple Myeloma

3. Epidemiology Forecast Flow

4. Disease Background and Overview: Multiple Myeloma

4.1. Introduction

4.2. Multiple Myeloma features

4.2.1. Low blood counts

4.2.2. Bone and calcium problems

4.2.3. Infections

4.2.4. Kidney problems

4.3. Causes of Multiple Myeloma

4.4. Risk factors of Multiple Myeloma

4.5. Signs and Symptoms

4.5.1. Bone Problems

4.5.2. Low blood counts

4.5.3. High blood levels of calcium

4.5.4. Nervous system symptoms

4.5.5. Kidney Problems

4.5.6. Infections

4.6. Pathogenesis of Multiple Myeloma

4.6.1. Molecular mechanisms underlying the progression of multiple myeloma

4.6.2. Molecular pathogenesis of multiple myeloma and its premalignant precursor

4.7. Pathophysiology of Multiple Myeloma

4.8. Patient-related risk factors

4.9. Biomarkers for Multiple Myeloma

4.9.1. Serum M-protein and light chains as biomarkers

4.9.2. Potential proteomic biomarkers

4.9.3. Cytogenetic biomarkers in multiple myeloma

5. Diagnosis of Multiple Myeloma

5.1. Lab tests

5.2. Biopsies

5.3. Imaging tests

5.4. Stages of Multiple Myeloma

6. Epidemiology and Patient Population

6.1. Epidemiology Key Findings

6.2. Assumptions and Rationale: 8MM

6.3. Epidemiology Scenario: 8MM

6.3.1. Total Incident Cases of Multiple Myeloma in the 8MM

6.3.2. Total Symptomatic Cases of Multiple Myeloma in the 8MM

6.3.3. Gender-specific cases of Multiple Myeloma in the 8MM

6.3.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM

6.3.5. Cases of Multiple Myeloma by Treatment Line in the 8MM

7. The United States Epidemiology

7.1. Total Incident Cases of Multiple Myeloma in the United States

7.2. Total Symptomatic Cases of Multiple Myeloma in the United States

7.3. Gender-specific cases of Multiple Myeloma in the United States

7.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United States

7.5. Cases of Multiple Myeloma by Treatment Line in the United States

8. EU-5 Epidemiology

8.1. Germany

8.1.1. Total Incident Cases of Multiple Myeloma in Germany

8.1.2. Total Symptomatic Cases of Multiple Myeloma in Germany

8.1.3. Gender-specific cases of Multiple Myeloma in Germany

8.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Germany

8.1.5. Cases of Multiple Myeloma by Treatment Line in Germany

8.2. France

8.2.1. Total Incident Cases of Multiple Myeloma in France

8.2.2. Total Symptomatic Cases of Multiple Myeloma in France

8.2.3. Gender-specific cases of Multiple Myeloma in France

8.2.4. Diagnosed cases of Multiple Myeloma by Age Distribution in France

8.2.5. Cases of Multiple Myeloma by Treatment Line in France

8.3. Italy

8.3.1. Total Incident Cases of Multiple Myeloma in Italy

8.3.2. Total Symptomatic Cases of Multiple Myeloma in Italy

8.3.3. Gender-specific cases of Multiple Myeloma in Italy

8.3.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Italy

8.3.5. Cases of Multiple Myeloma by Treatment Line in Italy

8.4. Spain

8.4.1. Total Incident Cases of Multiple Myeloma in Spain

8.4.2. Total Symptomatic Cases of Multiple Myeloma in Spain

8.4.3. Gender-specific cases of Multiple Myeloma in Spain

8.4.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Spain

8.4.5. Cases of Multiple Myeloma by Treatment Line in Spain

8.5. The United Kingdom

8.5.1. Total Incident Cases of Multiple Myeloma in the United Kingdom

8.5.2. Total Symptomatic Cases of Multiple Myeloma in the United Kingdom

8.5.3. Gender-specific cases of Multiple Myeloma in the United Kingdom

8.5.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom

8.5.5. Cases of Multiple Myeloma by Treatment Line in the United Kingdom

9. Japan Epidemiology

9.1. Japan

9.1.1. Total Incident Cases of Multiple Myeloma in Japan

9.1.2. Total Symptomatic Cases of Multiple Myeloma in Japan

9.1.3. Gender-specific cases of Multiple Myeloma in Japan

9.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Japan

9.1.5. Cases of Multiple Myeloma by Treatment Line in Japan

10. China Epidemiology

10.1. China

10.1.1. Total Incident Cases of Multiple Myeloma in China

10.1.2. Total Symptomatic Cases of Multiple Myeloma in China

10.1.3. Gender-specific cases of Multiple Myeloma in China

10.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in China

10.1.5. Cases of Multiple Myeloma by Treatment Line in China

11. Appendix

11.1. Bibliography

11.2. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

List of Table

Table 1: Summary of Multiple Myeloma; Epidemiology, and Key Events (2017–2030)

Table 2: Cytogenetic Abnormalities on Clinical Course and Prognosis in Multiple Myeloma

Table 3: The Revised International Staging System

Table 4: International Myeloma Working Group (IMWG) Diagnostic Criteria for Multiple Myeloma and Related Plasma Cell Disorders

Table 5: Recommendations for the use of ¹⁸F-FDG PET/CT in patients with multiple myeloma and other plasma cell disorders

Table 6: Guidelines for the first-line treatment of multiple myeloma

Table 7: Recommendations for the management of relapsed or refractory multiple myeloma

Table 8: Total Incident Cases of Multiple Myeloma in the 8MM (2017–2030)

Table 9: Total Symptomatic Cases of Multiple Myeloma in the 8MM (2017–2030)

Table 10: Gender-specific cases of Multiple Myeloma in the 8MM (2017–2030)

Table 11: Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM (2017–2030)

Table 12: Cases of Multiple Myeloma by Treatment Line in the 8MM (2017–2030)

Table 13: Total Incident Cases of Multiple Myeloma in the United States (2017–2030)

Table 14: Total Symptomatic Cases of Multiple Myeloma in the United States (2017–2030)

Table 15: Gender-specific cases of Multiple Myeloma in the United States (2017–2030)

Table 16: Diagnosed cases of Multiple Myeloma by Age Distribution in the United States (2017–2030)

Table 17: Cases of Multiple Myeloma by Treatment Line in the United States (2017–2030)

Table 18: Total Incident Cases of Multiple Myeloma in Germany (2017–2030)

Table 19: Total Symptomatic Cases of Multiple Myeloma in Germany (2017–2030)

Table 20: Gender-specific cases of Multiple Myeloma in Germany (2017–2030)

Table 21: Diagnosed cases of Multiple Myeloma by Age Distribution in Germany (2017–2030)

Table 22: Cases of Multiple Myeloma by Treatment Line in Germany (2017–2030)

Table 23: Total Incident Cases of Multiple Myeloma in France (2017–2030)

Table 24: Total Symptomatic Cases of Multiple Myeloma in France (2017–2030)

Table 25: Gender-specific cases of Multiple Myeloma in France (2017–2030)

Table 26: Diagnosed cases of Multiple Myeloma by Age Distribution in France (2017–2030)

Table 27: Cases of Multiple Myeloma by Treatment Line in France (2017–2030)

Table 28: Total Incident Cases of Multiple Myeloma in Italy (2017–2030)

Table 29: Total Symptomatic Cases of Multiple Myeloma in Italy (2017–2030)

Table 30: Gender-specific cases of Multiple Myeloma in Italy (2017–2030)

Table 31: Diagnosed cases of Multiple Myeloma by Age Distribution in Italy (2017–2030)

Table 32: Cases of Multiple Myeloma by Treatment Line in Italy (2017–2030)

Table 33: Total Incident Cases of Multiple Myeloma in Spain (2017–2030)

Table 34: Total Symptomatic Cases of Multiple Myeloma in Spain (2017–2030)

Table 35: Gender-specific cases of Multiple Myeloma in Spain (2017–2030)

Table 36: Diagnosed cases of Multiple Myeloma by Age Distribution in Spain (2017–2030)

Table 37: Cases of Multiple Myeloma by Treatment Line in Spain (2017–2030)

Table 38: Total Incident Cases of Multiple Myeloma in the United Kingdom (2017–2030)

Table 39: Total Symptomatic Cases of Multiple Myeloma in the United Kingdom (2017–2030)

Table 40: Gender-specific cases of Multiple Myeloma in the United Kingdom (2017–2030)

Table 41: Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom (2017–2030)

Table 42: Cases of Multiple Myeloma by Treatment Line in the United Kingdom (2017–2030)

Table 43: Total Incident Cases of Multiple Myeloma in Japan (2017–2030)

Table 44: Total Symptomatic Cases of Multiple Myeloma in Japan (2017–2030)

Table 45: Gender-specific cases of Multiple Myeloma in Japan (2017–2030)

Table 46: Diagnosed cases of Multiple Myeloma by Age Distribution in Japan (2017–2030)

Table 47: Cases of Multiple Myeloma by Treatment Line in Japan (2017–2030)

Table 48: Total Incident Cases of Multiple Myeloma in China (2017–2030)

Table 49: Total Symptomatic Cases of Multiple Myeloma in China (2017–2030)

Table 50: Gender-specific cases of Multiple Myeloma in China (2017–2030)

Table 51: Diagnosed cases of Multiple Myeloma by Age Distribution in China (2017–2030)

Table 52: Cases of Multiple Myeloma by Treatment Line in China (2017–2030)

List of Figures

Figure 1: Interactions of MM tumor cells with the BM microenvironment. Five kinds of cells in the BM microenvironment are depicted, as well as a few of the complex interactions among these cells and MM cells.

Figure 2: Interaction of multiple myeloma cells in their bone marrow milieu

Figure 3: Technological advances in detecting biomarkers in multiple myeloma.

Figure 4: The National Comprehensive Cancer Network (NCCN) recommendations for initial diagnostic workup of patients with suspected MM

Figure 5: Factors influencing the choice of therapy at relapse

Figure 6: Treatment algorithm for Relapsing Refractory Multiple Myeloma

Figure 7: Algorithm on treatment of patients with multiple myeloma

Figure 8: The NCCN Recommendations for follow-up of patients with MM after primary treatment

Figure 9: The NCCN Recommendations for Primary Myeloma Therapy

Figure 10: The NCCN Recommendations for Myeloma Therapy

Figure 11: The NCCN Recommendations for Lenalidomide Maintenance

Figure 12: The NCCN Recommendations for Management of Renal Disease in Patients With MM

Figure 13: Global Heat Map of Multiple Myeloma

Figure 14: Total Incident Cases of Multiple Myeloma in the 8MM (2017–2030)

Figure 15: Symptomatic Cases of Multiple Myeloma in the 8MM (2017–2030)

Figure 16: Gender-specific cases of Multiple Myeloma in the 8MM (2017–2030)

Figure 17: Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM (2017–2030)

Figure 18: Cases of Multiple Myeloma by Treatment Line in the 8MM (2017–2030)

Figure 19: Total Incident Cases of Multiple Myeloma in the United States (2017–2030)

Figure 20: Symptomatic Cases of Multiple Myeloma in the United States (2017–2030)

Figure 21: Gender-specific cases of Multiple Myeloma in the United States (2017–2030)

Figure 22: Diagnosed cases of Multiple Myeloma by Age Distribution in the United States (2017–2030)

Figure 23: Cases of Multiple Myeloma by Treatment Line in the United States (2017–2030)

Figure 24: Total Incident Cases of Multiple Myeloma in Germany (2017–2030)

Figure 25: Symptomatic Cases of Multiple Myeloma in Germany (2017–2030)

Figure 26: Gender-specific cases of Multiple Myeloma in Germany (2017–2030)

Figure 27: Diagnosed cases of Multiple Myeloma by Age Distribution in Germany (2017–2030)

Figure 28: Cases of Multiple Myeloma by Treatment Line in Germany (2017–2030)

Figure 29: Total Incident Cases of Multiple Myeloma in France (2017–2030)

Figure 30: Symptomatic Cases of Multiple Myeloma in France (2017–2030)

Figure 31: Gender-specific cases of Multiple Myeloma in France (2017–2030)

Figure 32: Diagnosed cases of Multiple Myeloma by Age Distribution in France (2017–2030)

Figure 33: Cases of Multiple Myeloma by Treatment Line in France (2017–2030)

Figure 34: Total Incident Cases of Multiple Myeloma in Italy (2017–2030)

Figure 35: Symptomatic Cases of Multiple Myeloma in Italy (2017–2030)

Figure 36: Gender-specific cases of Multiple Myeloma in Italy (2017–2030)

Figure 37: Diagnosed cases of Multiple Myeloma by Age Distribution in Italy (2017–2030)

Figure 38: Cases of Multiple Myeloma by Treatment Line in Italy (2017–2030)

Figure 39: Total Incident Cases of Multiple Myeloma in Spain (2017–2030)

Figure 40: Symptomatic Cases of Multiple Myeloma in Spain (2017–2030)

Figure 41: Gender-specific cases of Multiple Myeloma in Spain (2017–2030)

Figure 42: Diagnosed cases of Multiple Myeloma by Age Distribution in Spain (2017–2030)

Figure 43: Cases of Multiple Myeloma by Treatment Line in Spain (2017–2030)

Figure 44: Total Incident Cases of Multiple Myeloma in the United Kingdom (2017–2030)

Figure 45: Symptomatic Cases of Multiple Myeloma in the United Kingdom (2017–2030)

Figure 46: Gender-specific cases of Multiple Myeloma in the United Kingdom (2017–2030)

Figure 47: Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom (2017–2030)

Figure 48: Cases of Multiple Myeloma by Treatment Line in the United Kingdom (2017–2030)

Figure 49: Total Incident Cases of Multiple Myeloma in Japan (2017–2030)

Figure 50: Symptomatic Cases of Multiple Myeloma in Japan (2017–2030)

Figure 51: Gender-specific cases of Multiple Myeloma in Japan (2017–2030)

Figure 52: Diagnosed cases of Multiple Myeloma by Age Distribution in Japan (2017–2030)

Figure 53: Cases of Multiple Myeloma by Treatment Line in Japan (2017–2030)

Figure 54: Total Incident Cases of Multiple Myeloma in China (2017–2030)

Figure 55: Symptomatic Cases of Multiple Myeloma in China (2017–2030)

Figure 56: Gender-specific cases of Multiple Myeloma in China (2017–2030)

Figure 57: Diagnosed cases of Multiple Myeloma by Age Distribution in China (2017–2030)

Figure 58: Cases of Multiple Myeloma by Treatment Line in China (2017–2030)

  • Tags:
  • Multiple Myeloma
  • Multiple Myeloma Epidemiology
  • Multiple Myeloma
  • Multiple Myeloma Pipeline
  • Multiple Myeloma Companies
  • Multiple Myeloma prevalent populat...
  • Multiple Myeloma incident populati...
  • Multiple Myeloma patients diagnose...
  • Multiple Myeloma treatment algorit...

Forward to Friend

Need A Quote